Laghezza Antonio, Piemontese Luca, Brunetti Leonardo, Caradonna Alessia, Agamennone Mariangela, Di Pizio Antonella, Pochetti Giorgio, Montanari Roberta, Capelli Davide, Tauro Marilena, Loiodice Fulvio, Tortorella Paolo
Department of Pharmacy and Pharmaceutical Sciences, University of Bari "A. Moro", via E. Orabona 4, 70125 Bari, Italy.
Department of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara, Via Dei Vestini, 31, 66100 Chieti, Italy.
Pharmaceuticals (Basel). 2020 Jun 1;13(6):113. doi: 10.3390/ph13060113.
Matrix metalloproteinases (MMPs) are a family of enzymes involved at different stages of cancer progression and metastasis. We previously identified a novel class of bisphosphonic inhibitors, selective for MMPs crucial for bone remodeling, such as MMP-2. Due to the increasing relevance of specific MMPs at various stages of tumor malignancy, we focused on improving potency towards certain isoforms. Here, we tackled MMP-9 because of its confirmed role in tumor invasion, metastasis, angiogenesis, and immuno-response, making it an ideal target for cancer therapy. Using a computational analysis, we designed and characterized potent MMP-2/MMP-9 inhibitors. This is a promising approach to develop and clinically translate inhibitors that could be used in combination with standard care therapy for the treatment of skeletal malignancies.
基质金属蛋白酶(MMPs)是一类参与癌症进展和转移不同阶段的酶。我们之前鉴定出了一类新型双膦酸抑制剂,它们对骨重塑至关重要的MMPs具有选择性,比如MMP-2。由于特定MMPs在肿瘤恶性发展的各个阶段的相关性日益增加,我们专注于提高对某些亚型的效力。在此,我们研究MMP-9,因为它在肿瘤侵袭、转移、血管生成和免疫反应中已被证实的作用,使其成为癌症治疗的理想靶点。通过计算分析,我们设计并表征了强效的MMP-2/MMP-9抑制剂。这是一种开发抑制剂并将其临床转化的有前景的方法,这些抑制剂可与标准护理疗法联合用于治疗骨骼恶性肿瘤。